Aranesp's life signs

It's not often that everyone is happy with a study that misses its primary endpoint, but that's exactly what happened last week, when Amgen Inc. reported top-line results from Study 145 of Aranesp darbepoetin alfa in advanced small cell lung cancer. The key was that there were not

Read the full 482 word article

How to gain access

Continue reading with a
two-week free trial.